HB-19

N/A

Report date: 2025/02/01 20:00:06

Base Information

Drug NameHB-19

Drug Alias Nameelongation factor Tu/host cell nucleolin interaction inhibitors (INSERM)Nucleolin Inhibitor (Centre National de la Recherche Scientifique (CNRS)/INSERM)HB-19-analog pseudopeptides (INSERM)HB-19

ClassificationBiologics > Protein drugs > Recombinant polypeptide

Mechanisms of ActionCell adhesion molecules inhibitorsNucleolin modulators

TargetsNucleolinCell adhesion molecules

Therapy Area/IndicationsNeoplasmsHIV InfectionsTularemia

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryFrance

CombinationsNo

Global Highest StatusPending (Preclinical)

Highest Status in ChinaN/A

Originator CompaniesInstitut Pasteur

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesInstitut National De La Sante Et De La Recherche Medicale Inserm Transfert Centre National De La Recherche Scientifique (Cnrs) +[4]

Active IndicationsN/A

Inactive IndicationsNeoplasmsHIV InfectionsTularemia

Other Information

ATC CodeN/A